Molecular characterization and therapeutic reaction to dasatinib in a CML patient harboring a novel e8a2 BCR-ABL1 transcript with a somatic mutation in TP53BP2 and cadherin-10 genes.
- Resource Type
- Case Study
- Authors
- Zhang, Yang; Cheng, Zhao; Yan, Wen-Zhe; Liu, Su-Fang; Hu, Chun-Hong; Zhang, Guang-Sen
- Source
- Leukemia & Lymphoma. Jan2018, Vol. 59 Issue 1, p233-236. 4p.
- Subject
- *DASATINIB
*DRUG side effects
*TREATMENT of chronic myeloid leukemia
*CHRONIC myeloid leukemia
*CANCER relapse
*PATIENTS
- Language
- ISSN
- 1042-8194
The article presents a case study of a reaction to the dasatinib drug in a 49-year-old man with chronic myeloid leukemia (CML) harboring a e8a2 BCR-ABL1 transcript gene with a somatic mutation of TP53BP2 and cadherin-10 (CDH10) gene. The patient was diagnosed with CML harboring the e8a2 transcript, and his variant BCR-ABL1:ABL1 ratio was revealed. He obtained complete remission at the molecular and hematological level.